New Product Launch

On November 4, 2025, the "Human Rhinovirus / Human Bocavirus / Human Metapneumovirus Nucleic Acid Detection Kit (Fluorescent PCR Method)" developed by XABT has been reviewed and officially approved for marketing by the National Medical Products Administration (NMPA) (Approval No.: 20253402203).

Filling Detection Gaps, Enabling Rapid and Accurate Diagnosis

Human Rhinovirus (HRV), Human Bocavirus (HBoV), and Human Metapneumovirus (HMPV) are common viral pathogens in acute respiratory infections, posing significant threats especially to children under 5 years old and the elderly. However, due to insufficient clinical awareness and limitations of traditional detection methods, diagnosis for these viruses often has "blind spots", leading to an increased risk of missed detection.

01 Human Rhinovirus (HRV)

As one of the most common pathogens in human respiratory infections, HRV is not only the main cause of the common cold (accounting for approximately 10%–20% of adult cold cases and 15%–30% of infant cold cases), but also closely associated with lower respiratory tract infections such as bronchiolitis, pneumonia, and acute asthma exacerbations. Although most HRV infections are self-limiting, they may still induce severe complications such as acute asthma attacks and heart failure, and are often complicated with other respiratory viral infections.

02 Human Bocavirus (HBoV)

HBoV is a non-enveloped single-stranded DNA virus first discovered in 2005, with year-round incidence, mainly affecting children under 3 years old. The incidence of HBoV infection in this population ranges from 1.5% to 22.5%. In addition, it is also a common pathogen of community-acquired pneumonia in adults. Common symptoms after infection include cough, nasal congestion, runny nose, fever, wheezing, pharyngeal congestion, and dyspnea.

03 Human Metapneumovirus (HMPV)

HMPV is an important respiratory pathogen second only to Respiratory Syncytial Virus (RSV), with sporadic occurrence throughout the year and high incidence in late winter and early spring. Its clinical manifestations are similar to RSV, with common symptoms including cough, wheezing, and fever. Approximately 30%–56% of children with HMPV infection develop wheezing. HMPV infection can progress to severe pneumonia and even respiratory failure. In China, HMPV ranks sixth (7.8%) in the detection rate of viral pathogens in children with community-acquired pneumonia (CAP), and third (12.7%) in children with severe CAP.

Detection using multiplex PCR technology can rapidly and accurately identify pathogens, guide rational clinical medication, and effectively avoid antibiotic abuse; meanwhile, it can assist in evaluating disease severity and prognosis, ultimately helping physicians formulate individualized and precise medical decisions. This is particularly important for patients with acute respiratory infections in emergency departments, pediatrics, respiratory departments, and ICUs.

To this end, XABT officially launches the "Human Rhinovirus / Human Bocavirus / Human Metapneumovirus Nucleic Acid Detection Kit (Fluorescent PCR Method)". As a powerful supplement to routine respiratory virus nucleic acid detection, this kit can accurately fill detection gaps; combined with a rapid detection protocol, it can complete the entire workflow within 30 minutes, providing rapid and accurate nucleic acid evidence support for outpatient and emergency diagnosis and treatment during high-incidence seasons.

6+3: Building a More Comprehensive Respiratory Virus Detection Defense

Combining the "Human Rhinovirus / Human Bocavirus / Human Metapneumovirus Nucleic Acid Triple Detection Kit" with the "Respiratory Virus Nucleic Acid Six Detection Kit" can further expand the detection range of common respiratory viruses, covering approximately 95% of common respiratory viral pathogens; thereby forming a more systematic and comprehensive respiratory virus diagnosis solution, assisting clinical practice in achieving earlier intervention and more precise treatment.

In response to the diagnostic needs of respiratory infections, our company launches a "Fast, Accurate, and Comprehensive" nucleic acid detection solution. Through a series of small panel detection combinations, this solution can fully cover viruses, bacteria, fungi, and atypical pathogens. It can not only tailor efficient detection schemes for rapid triage in outpatient and emergency departments, but also customize reliable detection schemes for precise diagnosis and treatment in inpatient departments, achieving scenario-based precise matching.